LYEL compared with SPRO: revenue, margins and what each company keeps, and the suppliers and customers both name

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

SPROSpero Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LYELLyell Immunopharma, Inc.

SPROSpero Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LYEL 11

—City of Hope Comprehensive Cancer Centerunlistedsupplier

—Dana Farber Cancer Instituteunlistedsupplier

—Innovative Cellular Therapeutics Holdings Limited and Innovative Cellular Therapeutics, Inc. (together, ICT)unlistedsupplier

—Miltenyi CliniMACS PRODIGY ®unlistedsupplier

7 more · LYEL chain ›

Shared 0

No shared counterparties.

Only SPRO 7

PFEPfizersupplier

GSKGSKcustomer

—Meijiunlistedsupplier

—Cantab Anti-Infectives

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

unlisted

supplier

3 more · SPRO chain ›

LYELLyell Immunopharma, Inc.

10.79▼−0.86%· post 10.79· delayed

Mkt cap$266.6MRevenue$4,000Q2 FY26Revenue$36,000FY25

SPROSpero Therapeutics, Inc.

1.05▲+0.48%· post 1.05· delayed

After hoursNov 3 '26delayed

Mkt cap$60.6MRevenue$258,000Q1 FY26Revenue$67MFY25

Compare

After hoursNov 3 '26delayed

LYELLyell Immunopharma, Inc.

SPROSpero Therapeutics, Inc.

10.79▼−0.86%post 10.79delayed

Price

1.05▲+0.48%post 1.05delayed

$266.6M

Mkt cap

$60.6M

Q2 FY26$4,000

Revenue

$258,000Q1 FY26

FY25$36,000

Revenue

$67MFY25

LYEL10.79▼−0.86%vsSPRO1.05▲+0.48%After hoursNov 3 '26delayed